Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
TRELSTAR (triptorelin pamoate) is a GnRH agonist administered as an intramuscular injection for the treatment of advanced prostate cancer and endometriosis-related conditions. It works by suppressing luteinizing hormone and follicle-stimulating hormone, leading to reduced testosterone or estrogen production. The product has been on the market since 2001 and serves patients requiring hormone suppression therapy.
With LOE approaching and modest Part D spending of $14M, the brand team is likely in maintenance mode with limited growth investments and consolidating headcount.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis
Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer
Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study
Worked on TRELSTAR at Verity Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
With zero linked job openings and LOE approaching, TRELSTAR offers limited career growth opportunities. This is a sunset-phase product where roles are primarily defensive, focused on maintaining market share and managing generic transition rather than driving innovation or expansion.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo